U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT07508007) titled 'Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings' on March 27.
Brief Summary: Lipoprotein(a) [Lp(a)] is recognised as an independent, non-modifiable genetic risk factor for cardiovascular (CV) disease. Current guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) recommend that Lp(a) be measured at least once in every adult's lifetime, however routine Lp(a) testing rates remains infrequent.
The aim of this study is to assess the impact of implementation strategies (IStr) designed to increase the adoption of Lp(a) testing in routine practice, ultimately...